Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Sustained delivery of functional vascular endothelial growth factor from nanoporous silica nanoparticles into a fibrin gel

Besecke K., Zippusch S., Helms F., Böer U., Wilhelmi M., Behrens P.

Laboratory Study on Face & Skin, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
PLoS One (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40569914
PMCID
PMC12200659
DOI
10.1371/journal.pone.0326561

Abstract (original English)

The unsolved major issue of large-scale tissue engineering scaffolds is insufficient initial vascularization. The lack of oxygen and nutrient supply for migrating cells inevitably leads to cell death and subsequently to implant failure. One approach to resolve this problem is the development of pre-vascularized tissue constructs. Following this idea, the installation of micro-vessels within a fibrin scaffold is a promising approach. To induce the formation of these micro-vessels a long-term release of vascular endothelial growth factor (VEGF), which is a key player in endothelial growth, is necessary. As drug carriers, nanoporous silica nanoparticles (NPSNPs) were chosen and loaded with VEGF by the interaction with grafted amino groups. Physicochemical characterization (TEM, XRD, N2 physisorption, zeta potential, and thermogravimetric analysis) revealed nanoparticles with approximately 44 nm in diameter, pore sizes of 3 nm, and a successful amino modification of the surface. The recorded release profiles showed a possible long-term release of up to 100 days. With adapted loading concentrations for in vitro testing, the released doses were applied within an in vitro 2D sandwich tube assay with endothelial cells and compared to repeatedly given doses of VEGF in solution. The VEGF released from the NPSNPs led to an equal tube formation, which qualifies them as an effective tool fo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansSilicon DioxideVascular Endothelial Growth Factor AFibrinGelsDelayed-Action PreparationsDrug CarriersDrug Delivery SystemsTissue EngineeringNanoparticles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research